Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils

Pharmacology, Biochemistry, and Behavior
N SaloméGuy Griebel

Abstract

There is a growing interest in the potential anxiolytic- and antidepressant-like effects of compounds that target neurokinin receptors. Since the structure and the pharmacology of the human neurokinin receptor resembles that of gerbils, rather than that of mice or rats, we decided to investigate the anxiolytic- and /or antidepressant-like effects of NK1 (SSR240600), NK2 (saredutant) and NK3 (osanetant) receptor antagonists in gerbils. It was found that saredutant (3-10 mg/kg, p.o.) and osanetant (3-10 mg/kg, p.o.) produced anxiolytic-like effects in the gerbil social interaction test. These effects were similar to those obtained with the V1b receptor antagonist SSR149415 (3-10 mg/kg, p.o.), diazepam (1 mg/kg, p.o.) and buspirone (10 mg/kg, p.o.). Fluoxetine and SSR240600 were devoid of effects in this test. In the tonic immobility test in gerbils, saredutant (5-10 mg/kg, i.p.) and osanetant (5-10 mg/kg, i.p.) produced similar effects to those observed with fluoxetine (7.5-15 mg/kg, i.p.), SSR149415 (10-30 mg/kg, p.o.) and buspirone (3 mg/kg, i.p.). Diazepam and SSR240600 were inactive in this paradigm. In conclusion, the present study indicates further that NK2 and NK3 receptor antagonists may have therapeutic potential in the ...Continue Reading

Citations

Apr 27, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jeanne StemmelinGuy Griebel
Jan 4, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Sanjay J MathewDennis S Charney
Dec 14, 2011·Current Opinion in Psychiatry·Jozsef Haller, Mano Alicki
Feb 12, 2011·Expert Review of Gastroenterology & Hepatology·Daniel P HolschneiderEmeran A Mayer
Oct 1, 2007·Expert Opinion on Drug Discovery·Chad E Beyer, Zoë A Hughes
May 12, 2009·Expert Opinion on Investigational Drugs·Shrinivas K Kulkarni, Ashish Dhir
Feb 15, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Parichehr Hassanzadeh, Anna Hassanzadeh
Feb 24, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·S SchäbleM A de Souza Silva
Jun 23, 2009·Neuropharmacology·Rebecca E NordquistWill Spooren
Jul 8, 2008·Biochemical Pharmacology·Ingela AhlstedtErik Lindström
May 12, 2009·Biochemical Pharmacology·Agnes LefflerBengt von Mentzer
Aug 31, 2007·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·L A HoughtonP J Whorwell
Sep 18, 2012·Neuroscience and Biobehavioral Reviews·J HallerK Gyimesine Pelczer
Jun 15, 2012·The International Journal of Neuropsychopharmacology·Alessandra TamburellaSalvatore Salomone
Dec 19, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Catherine Belzung
Dec 7, 2013·Journal of Clinical Psychopharmacology·Joel Sadavoy, Jerald Bain
Apr 20, 2021·Biological Psychiatry·A Shaam Al AbedNathalie Dehorter
Sep 15, 2020·ACS Chemical Neuroscience·Wen-Wen ZhangYu-Xia Chu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Barrel cortex

Here is the latest research on barrel cortex, a region of somatosensory and motor corticies in the brain, which are used by animals that rely on whiskers for world exploration.

Amygdala: Sensory Processes

Amygdalae, nuclei clusters located in the temporal lobe of the brain, play a role in memory, emotional responses, and decision-making. Here is the latest research on sensory processes in the amygdala.

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.